MyoKardia

Sanofi, MyoKardia collaborate on genetic heart disease

Thursday, September 18, 2014

Sanofi and MyoKardia, a South San Francisco-based, privately held company developing precision therapies for genetic heart disease, are collaborating to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease. The collaboration builds upon MyoKardia’s pioneering science, which hopes to correct the disruptive effects that disease mutations have on heart muscle contraction.

[Read More]